The path to appropriate biosimilar management | Magellan Health Insights

The path to appropriate biosimilar management | Magellan Health Insights

The path to appropriate biosimilar management

by Magellan Health Insights

May 10, 2021 Biosimilar, Biosimilar Management, Biosimilars, FDA, Magellan Health, Magellan Healthcare, Magellan RX, Magellan Rx Management, Medical Benefit, Oncology Biosimilars, Specialty Pharmacy

Traditional Drug to Biologic: A Change 10 Years in the Making

by Magellan Health Insights

June 22, 2020 Biologics, Biosimilars, Drug Approvals, FDA, Magellan, Magellan Health, Magellan Healthcare

The Quest for the Hepatitis C Virus Holy Grail

by Magellan Health Insights

June 19, 2017 Breakthrough Therapy Designation, Genotypes, HCV, Hepatits C, Magellan Health, Pangenotypic

Do You Know the Truth about Trend?

by Magellan Health Insights

June 5, 2017 Magellan Rx Management, Medical Pharmacy, Pharmacy Spend, Specialty, Trend

What is Hedis and What does it mean to you?

How Can You Better Understand The Impact of High-Cost Specialty Drugs Billed on the Medical Benefit?

by Magellan Health Insights

April 12, 2017 Casandra Stockman, Medical Benefit, PBM, Specialty Pharmacy

Calling all speakers for Magellan Rx Management’s 2017 Specialty Summit

by Magellan Health Insights

February 9, 2017 Magellan Rx Management, Mostafa Kamal, New York City, Specialty Summit

Part 2: Magellan Open Vision Exchange (MOVE) 2016 Recap

by Magellan Health Insights

November 1, 2016 Arizona, Barry Smith, Magellan Health, Magellan Healthcare, Magellan Rx Management, MOVE

A Value-Based PBM: Implications for Various Stakeholders

by Magellan Health Insights

October 13, 2016 Dr. Karen Amstutz, Dr. Maria Lopes, Magellan Health, Magellan Rx Management, Oncology, PBM, Pharmacy, Pharmacy Benefit Management, Specialty Pharmacy, Value-Based